Clinical Trial Update: To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing safety and tolerability of an oral aripiprazole/escitalopram combination in adults with major depressive disorder was terminated; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• aripiprazole/escitalopram combination therapy

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Major Depressive Disorder (MDD) | Phase 3 | Status: TERMINATED | Results posted: 2021-12-22